Overview
Glutathione (GSH) is a tripeptide of glutamine, cysteine and glycine, produced mainly by the liver, and it is the most abundant endogenous antioxidant (Fathizadeh 2026, Richie 2015). This article summarises the published trials on body GSH stores and the reviews on skin pigmentation, and states where the evidence is weak. Stackpure supplies L-glutathione for laboratory research only.
Body stores in oral trials
A 6-month randomized, placebo-controlled trial in 54 adults gave oral GSH at 250 or 1,000 mg/day. Blood GSH rose at both doses. At 6 months in the high-dose group, GSH rose 30 to 35% in erythrocytes, plasma and lymphocytes and 260% in buccal cells, and levels returned to baseline after a 1-month washout (Richie 2015). A 1-month pilot study of liposomal GSH in 12 adults at 500 and 1,000 mg/day found maximum rises of 40% in whole blood and 100% in peripheral blood mononuclear cells at 2 weeks, with lower oxidative stress markers (Sinha 2018).
| Finding | Model | Source |
|---|---|---|
| Blood GSH up at 250 and 1,000 mg/day; high dose +30 to 35% in erythrocytes, plasma, lymphocytes at 6 months | Randomized placebo-controlled trial, 54 adults | Richie 2015 |
| Liposomal GSH: up to +40% whole blood, +100% PBMCs at 2 weeks | Pilot study, 12 adults, 1 month | Sinha 2018 |
| Oral skin-lightening: significant but variable melanin decreases | Narrative review | Alzahrani 2025 |
| Intravenous use linked to anaphylaxis and hepatotoxicity concerns; no standard dosing | Narrative review | Alzahrani 2025 |
| Absorption from the gut is poor; general consensus against the oral route for pigmentation | Clinical review | Sharma 2022 |
Skin pigmentation reviews
A narrative review found oral GSH gave significant but variable decreases in melanin with limited side effects, topical use gave good melanin reduction of varying sustainability, and intravenous use carried serious safety concerns including anaphylaxis and hepatotoxicity, with no standardized dosing. The authors call for large long-term trials (Alzahrani 2025). Another review notes poor absorption from the gastrointestinal tract and no clear published guidelines for management of pigmentation (Sharma 2022).
What the sources do not show
- The two trials differ in design and size, and the liposomal study was a 12-subject pilot.
- No source checked supports claims about detoxification beyond the general statements in reviews.
- Evidence for the vial format used in research is not covered by these clinical sources.
Related research products and tools
Frequently Asked Questions
What is glutathione?
A tripeptide of glutamine, cysteine and glycine and the most abundant endogenous antioxidant (Fathizadeh 2026, Richie 2015).
Does oral glutathione raise body levels?
In a 6-month randomized trial, blood GSH rose at 250 and 1,000 mg/day (Richie 2015).
Is absorption good?
A clinical review states absorption from the gastrointestinal tract is poor (Sharma 2022).
Key References
- Richie JP Jr, et al. Randomized controlled trial of oral glutathione supplementation on body stores of glutathione. Eur J Nutr. 2015. PubMed 24791752
- Sinha R, et al. Oral supplementation with liposomal glutathione elevates body stores of glutathione and markers of immune function. Eur J Clin Nutr. 2018. PubMed 28853742
- Alzahrani TF, et al. Exploring the safety and efficacy of glutathione supplementation for skin lightening: a narrative review. Cureus. 2025. PubMed 40013212
- Sharma DK, et al. Augmented glutathione absorption from oral mucosa and its effect on skin pigmentation: a clinical review. Clin Cosmet Investig Dermatol. 2022. PubMed 36117769
- Fathizadeh H, et al. A review of the potential benefits and limitations of oral glutathione supplementation. Inflammopharmacology. 2026. PubMed 42446814
For research use only. Not for human consumption.